News & Updates

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

29 Jan 2025

The combination of pembrolizumab plus bevacizumab shows promising activity against platinum-resistant nasopharyngeal carcinoma while having manageable toxicities, according to an open-label phase II study conducted in Singapore.

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

29 Jan 2025

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

29 Jan 2025 by

Long-term kidney outcomes in type 2 diabetes (T2D) are similar between empagliflozin- and dapagliflozin-treated patients, aligning with current clinical practice guidelines that do not favour one SGLT2 inhibitor over the other, according to a study.

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

29 Jan 2025

GLP-1 RAs reduce BP in overweight, obese patients

29 Jan 2025

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly lowers blood pressure (BP) in obese or overweight patients, according to a study. This beneficial effect persists across diabetic status, duration of treatment, and route of administration.

GLP-1 RAs reduce BP in overweight, obese patients

29 Jan 2025

One basal insulin noninferior to another in type 2 diabetes

29 Jan 2025

In the management of type 2 diabetes (T2D) in adults who are naïve to insulin, once-weekly efsitora alfa compares favourably with once-daily degludec in terms of lowering glycated haemoglobin levels, according to an open-label phase III study.

One basal insulin noninferior to another in type 2 diabetes

29 Jan 2025

Etavopivat reduces VOCs in patients with sickle cell disease

29 Jan 2025 by

Once-daily treatment with etavopivat results in lower rates of annualized vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) compared with placebo, according to the HIBISCUS trial presented at ASH 2024.

Etavopivat reduces VOCs in patients with sickle cell disease

29 Jan 2025

CKD predicts cardiac, cerebral events risk in patients with chronic coronary syndrome

28 Jan 2025

Among patients with chronic coronary syndrome, those with chronic kidney disease (CKD) at baseline are at increased risk of major adverse cardiac and cerebral events (MACCE), according to data from the REAL‐CAD* study.

CKD predicts cardiac, cerebral events risk in patients with chronic coronary syndrome

28 Jan 2025

Undernutrition impairs measles, tetanus vax responses in children

28 Jan 2025 by

Children who are undernourished may have a compromised immune response to certain vaccines, and this impaired response can contribute to the burden of vaccine-preventable diseases, according to the VHEMBE* South African birth cohort study.

Undernutrition impairs measles, tetanus vax responses in children

28 Jan 2025

PegIFN-α-2a lowers relapse in HBeAg-negative patients after NUC cessation

28 Jan 2025

Switching treatment from nucleo(s)tide analogue (NUC) to pegylated interferon alpha-2a (PegIFN-α-2a) for 48 weeks results in a significant decrease in virological relapse rates as well as higher hepatitis B surface antigen (HBsAg) loss rates when compared with NUC treatment cessation alone in patients with HBeAg-negative chronic hepatitis B, reports a study.

PegIFN-α-2a lowers relapse in HBeAg-negative patients after NUC cessation

28 Jan 2025

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

28 Jan 2025 by

A single tremelimumab regular interval durvalumab (STRIDE) provides survival benefits to Asian patients with unresectable hepatocellular carcinoma (HCC), as shown by the results of the HIMALAYA study.

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

28 Jan 2025

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

28 Jan 2025

In the treatment of patients with polymyalgia rheumatica, the Janus kinase 1/2 inhibitor baricitinib helps reduce the need to take oral glucocorticoids to have low disease activity while having no new safety signals, according to data from the randomized, double-blind BACHELOR trial.

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

28 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

GLP-1 RAs reduce BP in overweight, obese patients

GLP-1 RAs reduce BP in overweight, obese patients

One basal insulin noninferior to another in type 2 diabetes

One basal insulin noninferior to another in type 2 diabetes

Etavopivat reduces VOCs in patients with sickle cell disease

Etavopivat reduces VOCs in patients with sickle cell disease

CKD predicts cardiac, cerebral events risk in patients with chronic coronary syndrome

CKD predicts cardiac, cerebral events risk in patients with chronic coronary syndrome

Undernutrition impairs measles, tetanus vax responses in children

Undernutrition impairs measles, tetanus vax responses in children

PegIFN-α-2a lowers relapse in HBeAg-negative patients after NUC cessation

PegIFN-α-2a lowers relapse in HBeAg-negative patients after NUC cessation

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

Baricitinib cuts need for oral steroids in polymyalgia rheumatica